PMID- 38538317
OWN - NLM
STAT- MEDLINE
DCOM- 20240329
LR  - 20240511
IS  - 1880-9952 (Electronic)
IS  - 1346-4280 (Print)
IS  - 1346-4280 (Linking)
VI  - 64
IP  - 1
DP  - 2024
TI  - Diverse B-cell tumors associated with t(14;19)(q32;q13)/IGH::BCL3 identified by 
      G-banding and fluorescence in situ hybridization.
PG  - 21-31
LID - 10.3960/jslrt.23053 [doi]
AB  - We characterized 5 B-cell tumors carrying t(14;19)(q32;q13) that creates the 
      IGH::BCL3 fusion gene. The patients' ages ranged between 55 and 88 years. Two 
      patients presented with progression or recurrence of B-cell chronic lymphocytic 
      leukemia (B-CLL)/small lymphocytic lymphoma (SLL), two with diffuse large B-cell 
      lymphoma (DLBCL) of non-germinal center B-like phenotype, and the remaining one 
      with composite angioimmunoblastic T-cell lymphoma and Epstein-Barr virus-positive 
      DLBCL. The presence of t(14;19)(q32;q13) was confirmed by fluorescence in situ 
      hybridization (FISH), showing colocalization of 3' IGH and 3' BCL3 probes on 
      der(14)t(14;19) and 5' BCL3 and 5' IGH probes on der(19)t(14;19). One B-CLL case 
      had t(2;14)(p13;q32)/IGH::BCL11A, and 2 DLBCL cases had t(8;14)(q24;q32) or 
      t(8;11;14)(q24;q11;q32), both of which generated IGH::MYC by FISH, and showed 
      nuclear expression of MYC and BCL3 by immunohistochemistry. The IGH::BCL3 fusion 
      gene was amplified by long-distance polymerase chain reaction in 2 B-CLL/SLL 
      cases and the breakpoints occurred immediately 5' of BCL3 exon 1 and within the 
      switch region associated with IGHA1. The 5 cases shared IGHV preferentially used 
      in B-CLL cells, but the genes were unmutated in 2 B-CLL/SLL cases and 
      significantly mutated in the remaining 3. B-cell tumors with t(14;19)(q32;q13) 
      can be divided into B-CLL/SLL and DLBCL groups, and the anatomy of IGH::BCL3 in 
      the latter may be different from that of the former.
FAU - Ohno, Hitoshi
AU  - Ohno H
AD  - Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan.
FAU - Maekawa, Fumiyo
AU  - Maekawa F
AD  - Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan.
FAU - Hayashida, Masahiko
AU  - Hayashida M
AD  - Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan.
FAU - Nakagawa, Miho
AU  - Nakagawa M
AD  - Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan.
FAU - Fukutsuka, Katsuhiro
AU  - Fukutsuka K
AD  - Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan.
FAU - Matsumura, Mitsuko
AU  - Matsumura M
AD  - Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan.
FAU - Takeoka, Kayo
AU  - Takeoka K
AD  - Tenri Institute of Medical Research, Tenri Hospital, Tenri, Japan.
FAU - Maruyama, Wataru
AU  - Maruyama W
AD  - Department of Hematology, Tenri Hospital, Tenri, Japan.
FAU - Ukyo, Naoya
AU  - Ukyo N
AD  - Department of Hematology, Tenri Hospital, Tenri, Japan.
FAU - Sumiyoshi, Shinji
AU  - Sumiyoshi S
AD  - Department of Diagnostic Pathology, Tenri Hospital, Tenri, Japan.
FAU - Tanaka, Yasuhiro
AU  - Tanaka Y
AD  - Department of Hematology, Shinko Hospital, Tenri, Japan.
FAU - Haga, Hironori
AU  - Haga H
AD  - Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto 
      University, Tenri, Japan.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - J Clin Exp Hematop
JT  - Journal of clinical and experimental hematopathology : JCEH
JID - 101141257
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/genetics/pathology
MH  - In Situ Hybridization, Fluorescence
MH  - Translocation, Genetic
MH  - *Epstein-Barr Virus Infections/genetics
MH  - Herpesvirus 4, Human
MH  - *Lymphoma, Large B-Cell, Diffuse/genetics
MH  - Chromosomes, Human, Pair 14/genetics
PMC - PMC11079985
OTO - NOTNLM
OT  - 19)(q32
OT  - q13)/IGH::BCL3, B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, 
      diffuse large B-cell lymphoma, fluorescence in situ hybridization, 
      immunohistochemistry
OT  - t(14
EDAT- 2024/03/28 00:45
MHDA- 2024/03/29 06:46
PMCR- 2024/03/28
CRDT- 2024/03/27 22:43
PHST- 2024/03/29 06:46 [medline]
PHST- 2024/03/28 00:45 [pubmed]
PHST- 2024/03/27 22:43 [entrez]
PHST- 2024/03/28 00:00 [pmc-release]
AID - 23053 [pii]
AID - 10.3960/jslrt.23053 [doi]
PST - ppublish
SO  - J Clin Exp Hematop. 2024;64(1):21-31. doi: 10.3960/jslrt.23053.